Phase 1/2 clinical studies showed the safety of applying low-dose IL-2 in the treatment of patients with chronic graft-versus-host disease (GVHD) 25, hepatitis C virus (HCV)-induced vasculitis 26, and type 1 diabetes (T1D) 27. Here, IL2 is linked to chronic graft versus host disease.